BIIB · Categories · Downgrades
BIIB - Analyst downgrades
Biogen Inc. (BIIB) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for BIIB
- Biogen downgraded by HSBC Securities with a new price targetHSBC Securities downgraded Biogen from Hold to Reduce and set a new price target of $143.00
- Biogen downgraded by HSBC Securities with a new price targetHSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00
- Biogen downgraded by ArgusArgus downgraded Biogen from Buy to Hold
- Biogen downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Biogen from Overweight to Neutral and set a new price target of $138.00 from $315.00 previously
- Biogen downgraded by BMO Capital Markets with a new price targetBMO Capital Markets downgraded Biogen from Outperform to Market Perform and set a new price target of $164.00 from $230.00 previously
- Biogen downgraded by Stifel with a new price targetStifel downgraded Biogen from Buy to Hold and set a new price target of $175.00
- Biogen downgraded by Jefferies with a new price targetJefferies downgraded Biogen from Buy to Hold and set a new price target of $180.00 from $250.00 previously
- Biogen downgraded by NeedhamNeedham downgraded Biogen from Buy to Hold
- Biogen downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Biogen from Overweight to Equal-Weight and set a new price target of $204.00 from $285.00 previously
- Biogen downgraded by Wells Fargo with a new price targetWells Fargo downgraded Biogen from Overweight to Equal Weight and set a new price target of $240.00 from $315.00 previously
- Biogen downgraded by UBS with a new price targetUBS downgraded Biogen from Buy to Neutral and set a new price target of $276.00 from $311.00 previously
- Biogen downgraded by Stifel with a new price targetStifel downgraded Biogen from Buy to Hold and set a new price target of $223.00 from $304.00 previously
- Biogen downgraded by BMO Capital with a new price targetBMO Capital downgraded Biogen from Outperform to Market Perform and set a new price target of $238.00 from $260.00 previously
- Biogen downgraded by Guggenheim with a new price targetGuggenheim downgraded Biogen from Buy to Neutral and set a new price target of $202.00 from $290.00 previously
- Biogen downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Biogen from Overweight to Neutral and set a new price target of $216.00 from $362.00 previously
- Biogen downgraded by DZ Bank with a new price targetDZ Bank downgraded Biogen from Buy to Hold and set a new price target of $264.00